Somatostatin Receptor SSTR-2a Expression Is a Stronger Predictor for Survival Than Ki-67 in Pancreatic Neuroendocrine Tumors

Fraenkel, 2012, Epidemiology of gastroenteropancreatic neuroendocrine tumours., Best Pract Res Clin Gastroenterol, 26, 691, 10.1016/j.bpg.2013.01.006

Wei, 2014, Tumor-associated macrophages are a useful biomarker to predict recurrence after surgical resection of nonfunctional pancreatic neuroendocrine tumors., Ann Surg, 260, 1088, 10.1097/SLA.0000000000000262

Fazio, 2010, Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas., Cancer Treat Rev, 36, S87, 10.1016/S0305-7372(10)70026-8

Furukori, 2014, Clinicopathological features of small nonfunctioning pancreatic neuroendocrine tumours., World J Gastroenterol, 20, 17949, 10.3748/wjg.v20.i47.17949

Vinik, 2014, Advances in diagnosis and treatment of pancreatic neuroendocrine tumors., Endocr Pract, 20, 1222, 10.4158/EP14373.RA

Caplin, 2014, Lanreotide in metastatic enteropancreatic neuroendocrine tumors., N Engl J Med, 371, 224, 10.1056/NEJMoa1316158

Papotti, 2002, Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumorsa correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis., Virchows Arch, 440, 461, 10.1007/s00428-002-0609-x

Wolin, 2012, The expanding role of somatostatin analogs in the management of neuroendocrine tumors., Gastrointest Cancer Res, 5, 161

Modlin, 2010, Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours., Aliment Pharmacol Ther, 31, 169, 10.1111/j.1365-2036.2009.04174.x

Klimstra, 2010, The pathologic classification of neuroendocrine tumors., Pancreas, 39, 707, 10.1097/MPA.0b013e3181ec124e

Kloppel, 2010, The ENETS and AJCCUICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statement., Virchows Arch, 456, 595, 10.1007/s00428-010-0924-6

Elston, 2015, Increased SSTR2A and SSTR3 expression in SDH deficient pheochromocytomas and paragangliomas., Hum Pathol, 46, 390, 10.1016/j.humpath.2014.11.012

Houang, 2013, Phosphaturic mesenchymal tumors show positive staining for somatostatin receptor 2A (SSTR2A)., Hum Pathol, 44, 2711, 10.1016/j.humpath.2013.07.016

Korner, 2012, Somatostatin receptor subtype 2A immunohistochemistry using a new monoclonal antibody selects tumors suitable for in vivo somatostatin receptor targeting., Am J Surg Pathol, 36, 242, 10.1097/PAS.0b013e31823d07f3

Okuwaki, 2013, Clinicopathologic characteristics of pancreatic neuroendocrine tumors and relation of somatostatin receptor type 2A to outcomes., Cancer, 119, 4094, 10.1002/cncr.28341

Corleto, 2009, Somatostatin receptor subtypes 2 and 5 are associated with better survival in well-differentiated endocrine carcinomas., Neuroendocrinology, 89, 223, 10.1159/000167796

Zhou, 2012, Negative regulation of pancreatic and duodenal homeobox-1 by somatostatin receptor subtype 5., Mol Endocrinol, 26, 1225, 10.1210/me.2012-1095

de Herder, 2003, Somatostatin receptors in gastroenteropancreatic neuroendocrine tumours., Endocr Relat Cancer, 10, 451, 10.1677/erc.0.0100451

Appetecchia, 2010, Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives., J Exp Clin Cancer Res, 29, 1, 10.1186/1756-9966-29-19

Kimura, 1999, Immunohistochemical expression of somatostatin type 2A receptor in neuroendocrine tumors., Clin Cancer Res, 5, 3483

Ono, 2007, Somatostatin receptor subtypes in human non-functioning neuroendocrine tumors and effects of somatostatin analogue SOM230 on cell proliferation in cell line NCI-H727., Anticancer Res, 27, 2231

Kaemmerer, 2013, Correlation of monoclonal and polyclonal somatostatin receptor 5 antibodies in pancreatic neuroendocrine tumors., Int J Clin Exp Pathol, 6, 49

Scarpa, 2010, Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients., Mod Pathol, 23, 824, 10.1038/modpathol.2010.58

McCall, 2013, Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate., Am J Surg Pathol, 37, 1671, 10.1097/PAS.0000000000000089

Basturk, 2015, The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms., Am J Surg Pathol, 39, 683, 10.1097/PAS.0000000000000408